Search company, investor...

Predict your next investment

Corporate Venture
FINANCE | Investment Firms & Funds

Investments

34

Portfolio Exits

5

About Sham Innovation Sante

Sham Innovation Sante is an innovation capital vehicle-controlled and held by Sham, a mutual insurer specialized in risk management for health care, social welfare, and community health organizations. Advised by Turenne Capital, Sham Innovation Sante's mission is to support innovative businesses in the health care sector through the growth and development phases of their life cycle.

Headquarters Location

18 rue Edouard Rochet Cedex 08

France

Want to inform investors similar to Sham Innovation Sante about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Sham Innovation Sante News

Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D

Mar 27, 2023

Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D Paris, Nice, and Chicago, 12 May 2022 – Therapixel, designer and supplier of MammoScreen® an Artificial Intelligence software reading aid for mammography, announces today fundraising of 15 M€ in series B. This operation was led by Crédit Mutuel Innovation and CapHorn, joined by Verve, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement. This fundraising will enable Therapixel to accelerate its commercial presence in the United States, launch more unique features for MammoScreen, and push even further the boundaries of its intelligent reading aid for mammography. Armed with two FDA regulatory clearances in the United Stated for both 2D and 3D (tomosynthesis) mammography, MammoScreen is already being deployed across large networks of breast cancer screening clinics. MammoScreen uses a unique score, MammoScreen Score™ to signal at a glance the level of suspicion of a mammogram. This makes it possible to confirm the lesions that are certain and to save precious time with a faster reading of benign cases. Radiologists can thus feel more confident in their decision and spend more time on difficult cases that require more attention. Matthieu Leclerc-Chalvet, Chief Executive Officer of Therapixel states: “We are very satisfied to close this new round of financing with investors active in the field of digital health. These funds will allow us to grow our American team with new sales and support people and to ramp up our commercial activities. With an already strong pipeline, Therapixel is poised for significant growth and will have a decisive impact on breast cancer screening.” Pierre Fillard, Chief Scientific and Technology Officer and Founder of Therapixel continues: “This is a major step for Therapixel and I am proud of the achievements of our teams in collaboration with radiologists partners. We will accelerate the launch of a new generation of AI that will allow women to benefit from an earlier detection with less anxiety and radiologists to be assisted in the ever-growing demand for imaging. We will also advance the regulatory and clinical developments that will solidify our leading position as the AI solution of choice for radiologists reading mammography”. With this new round, Therapixel has raised more than 20 M€ since its founding in 2013. The following council and advisor helped with this round: Legal counsel: JonesDay – Renaud Bonnet Financial advisors: Fraser Finance – Olivier Koechlin and Deborah Herst Press contacts: Aurélie Blanchard-Massoni (Omnes Capital) aurelie.blanchard-massoni@www-rec.omnescapital.com Valérie Roché-Melin (Région Sud Investissement) – v.roche@regionsudinvestissement.com About : Therapixel is a French company specialized in the design and commercialization of AI-powered medical imaging software, with the goal of delivering pertinent information at the right time to healthcare professionals. Winner of the Digital Mammography DREAM Challenge in 2017, the global competition on breast cancer detection with AI, Therapixel has developed MammoScreen®, a software that helps with the interpretation of screening 2D and 3D mammograms. With MammoScreen, even experienced radiologists can improve their performance, feel more confident in their judgment, and reassure women quicker. Find more at www.mammoscreen.com

Sham Innovation Sante Investments

34 Investments

Sham Innovation Sante has made 34 investments. Their latest investment was in Amolyt Pharma as part of their Series C on January 1, 2023.

CBI Logo

Sham Innovation Sante Investments Activity

investments chart

Sham Innovation Sante Portfolio Exits

5 Portfolio Exits

Sham Innovation Sante has 5 portfolio exits. Their latest portfolio exit was CyberMDX on February 01, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/1/2022

Acquired

$99M

5

6/1/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/30/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/20/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/13/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/1/2022

6/1/2021

5/30/2018

12/20/2017

10/13/2017

Exit

Acquired

Acquired

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.